GKIM
JAZZ icon

GW&K Investment Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

GW&K Investment Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$70.2M Sell
371,098
-56,546
-13% -$9.88M 0.62% 38
2025
Q4 		$72.7M Sell
427,644
-27,068
-6% -$4.15M 0.63% 34
2025
Q3 		$59.9M Sell
454,712
-17,849
-4% -$2.14M 0.53% 57
2025
Q2 		$50.1M Buy
472,561
+2,015
+0.4% +$219K 0.45% 75
2025
Q1 		$58.4M Buy
470,546
+6,543
+1% +$854K 0.54% 52
2024
Q4 		$57.1M Buy
464,003
+97,589
+27% +$11.5M 0.49% 67
2024
Q3 		$40.8M Sell
366,414
-2,932
-0.8% -$321K 0.35% 113
2024
Q2 		$39.4M Buy
369,346
+5,600
+2% +$616K 0.36% 108
2024
Q1 		$43.8M Sell
363,746
-3,119
-0.9% -$382K 0.39% 108
2023
Q4 		$45.1M Sell
366,865
-19,980
-5% -$2.49M 0.42% 90
2023
Q3 		$50.1M Sell
386,845
-15,479
-4% -$2.06M 0.5% 74
2023
Q2 		$49.9M Sell
402,324
-9,802
-2% -$1.32M 0.47% 81
2023
Q1 		$60.3M Buy
412,126
+71,214
+21% +$10.5M 0.58% 54
2022
Q4 		$54.3M Sell
340,912
-9,019
-3% -$1.32M 0.55% 61
2022
Q3 		$46.6M Sell
349,931
-27,106
-7% -$4.12M 0.51% 68
2022
Q2 		$58.8M Sell
377,037
-42,705
-10% -$6.57M 0.63% 40
2022
Q1 		$65.3M Buy
419,742
+19,649
+5% +$2.85M 0.58% 48
2021
Q4 		$51M Buy
400,093
+134,029
+50% +$17.6M 0.43% 95
2021
Q3 		$34.6M Sell
266,064
-3,345
-1% -$505K 0.31% 144
2021
Q2 		$47.9M Buy
269,409
+3,962
+1% +$686K 0.42% 97
2021
Q1 		$43.6M Buy
265,447
+29,558
+13% +$4.86M 0.4% 103
2020
Q4 		$38.9M Buy
235,889
+14
+0% +$2.08K 0.41% 98
2020
Q3 		$33.6M Buy
235,875
+42,982
+22% +$5.33M 0.44% 90
2020
Q2 		$21.3M Buy
192,893
+1,375
+0.7% +$152K 0.3% 149
2020
Q1 		$19.1M Buy
191,518
+9,618
+5% +$1.24M 0.34% 124
2019
Q4 		$27.2M Sell
181,900
-5,788
-3% -$788K 0.36% 123
2019
Q3 		$24.1M Buy
187,688
+53,512
+40% +$7.17M 0.34% 134
2019
Q2 		$19.1M Buy
134,176
+1,188
+0.9% +$160K 0.29% 156
2019
Q1 		$19M Buy
132,988
+46,583
+54% +$6.08M 0.31% 150
2018
Q4 		$10.7M Buy
+86,405
New +$12.8M 0.21% 172

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

GW&K Investment Management's JAZZ Position: Q1 2026 in Review

GW&K Investment Management reduced its Jazz Pharmaceuticals (JAZZ) stake by 13% in Q1 2026, selling an estimated $9.88M and leaving 371,098 shares worth $70.2M. The position accounts for 0.62% of the portfolio, ranked #38.

GW&K Investment Management first reported a position in JAZZ in Q4 2018 and has held it in 30 quarters since. The position peaked at $72.7M in Q4 2025. 571 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • GW&K Investment Management held 371,098 shares of Jazz Pharmaceuticals worth $70.2M as of Q1 2026.
  • GW&K Investment Management sold 56,546 Jazz Pharmaceuticals shares in Q1 2026, an estimated $9.88M.
  • Jazz Pharmaceuticals made up 0.62% of GW&K Investment Management's portfolio in Q1 2026, its #38 holding.
  • GW&K Investment Management first reported a position in Jazz Pharmaceuticals in Q4 2018 and has held it in 30 quarters since.
  • GW&K Investment Management's Jazz Pharmaceuticals position peaked at $72.7M in Q4 2025.
  • 571 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on GW&K Investment Management's 13F filing for Q1 2026, filed 13 May 2026.